PFM Health Sciences: Holdings Comparison Q3 2022 vs. Q4 2022
Ava Hoppe | 11 May, 2023
In the world of finance, keeping track of the holdings of a hedge fund or investment firm is crucial. These holdings provide an insight into the firm's overall strategy and can predict its future success. One way to do this is through the 13F filings, which disclose the firm's holdings of publicly traded securities. In this blog post, we will explore the changes in holdings of PFM Health Sciences LP through the comparison of the Q3 2022 and Q4 2022 13F filings.
The PFM Health Sciences LP fund holds shares in several pharmaceutical and healthcare companies, including Horizon Therapeutics Pub L, Cytokinetics Inc, and Eli Lilly & Co. Let's look at several of the fund's notable position changes.
Horizon Therapeutics Pub L
During Q3 2022 and Q4 2022, PFM Health Sciences LP held 1,091,840 shares and maintained that position through both quarters. However, the value of the shares held increased by 83.9%, from $67,574,000 to $124,251,000, respectively.
Cytokinetics Inc
The PFM Health Sciences LP fund reduced its position in Cytokinetics Inc by 7.9%, holding 2,465,016 shares in Q3 2022, but only 2,399,545 in Q4 2022.
Eli Lilly & Co
The fund also increased its position in Eli Lilly & Co, holding 298,643 shares in both Q3 2022 and Q4 2022. However, the value of the shares held increased by 13.1%, from $96,566,000 to $109,255,000, respectively.
Merck & Co Inc
Merck & Co has two positions in PFM Health Sciences LP's portfolio, one being a call option and the other being a standard position. Notably, the fund acquired 871,500 shares of Merck & Co call option, which was absent in Q3 2022. The fund's other position of Merck & Co increased in shares from 360,520 to 367,634. The value of the standard position increased by 31.4%, from $31,048,000 to $40,788,000.
Centene Corp Del
The PFM Health Science LP fund increased its position in Centene Corp Del by 5.4%, holding 1,112,480 shares in both Q3 2022 and Q4 2022. However, the value of the shares held increased by only 5.4%, from $86,562,000 to $91,234,000, respectively.
UnitedHealth Group Inc
The PFM Health Science LP fund increased its position in UnitedHealth Group Inc by 9.2%, holding 111,554 shares in Q3 2022 and 116,067 shares in Q4 2022. However, the value of the shares held increased by only 9.2%, from $56,339,000 to $61,536,000, respectively.
In conclusion, PFM Health Sciences LP made several notable changes to their portfolio holdings in the pharmaceutical and healthcare sectors. While some positions decreased, others increased, and the fund acquired new positions. Despite the changes, the overall value of the fund's holdings increased from Q3 2022 to Q4 2022.
Other Posts
- A Comparative Analysis of Nuveen Fund Advisors, LLC Q2 2019 vs. Q3 2019 13F Holdings
- Carlisle Fluid Technologies Sold to Lone Star Funds: A New Era of Growth and Innovation
- MB2 Dental Breaks New Ground in West Virginia, Expanding Its National Footprint to 40 States
- Manor Road Capital's Q3 and Q4 13F filings reveal major portfolio changes, with elimination of holdings in Amazon, Facebook, and more.
- Ashburton Hospitality Advisors: Revolutionizing Asset Management in the Hospitality Industry
- Navigating the Tempest: Unveiling Q4 2023 to Q1 2024 Finance Sector Swells and Dips
- Analyzing Raymond James & Associates Q4 2022 vs. Q1 2023 13F Holdings: Winners, Losers, and What You Need to Know
- PFG Advisors Q1 2023 vs. Q2 2023 13F Holdings Comparison
- IMS Capital Management Q2 2023 vs. Q3 2023 13F Holdings Comparison
- One Equity Partners Sells Walki to Japan's Oji Group: A Win-Win for Sustainable Packaging